Schutter Richard U. De Buys 10,000 Shares of Valeant Pharmaceuticals International Inc (VRX) Stock

Share on StockTwits

Valeant Pharmaceuticals International Inc (NYSE:VRX) (TSE:VRX) Director Schutter Richard U. De purchased 10,000 shares of the business’s stock in a transaction that occurred on Thursday, March 8th. The stock was acquired at an average price of $15.34 per share, for a total transaction of $153,400.00. Following the acquisition, the director now owns 106,062 shares in the company, valued at approximately $1,626,991.08. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of NYSE:VRX opened at $15.44 on Friday. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 4.25. Valeant Pharmaceuticals International Inc has a 52-week low of $8.31 and a 52-week high of $24.43. The firm has a market capitalization of $5,508.19, a PE ratio of 4.03, a P/E/G ratio of 0.33 and a beta of -0.32.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last issued its quarterly earnings data on Wednesday, February 28th. The specialty pharmaceutical company reported $0.98 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.96 by $0.02. Valeant Pharmaceuticals International had a return on equity of 42.48% and a net margin of 27.56%. The business had revenue of $2.16 billion for the quarter, compared to the consensus estimate of $2.18 billion. During the same period in the prior year, the business earned $1.26 earnings per share. The business’s revenue was down 10.0% on a year-over-year basis. equities analysts anticipate that Valeant Pharmaceuticals International Inc will post 3.12 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Prime Capital Investment Advisors LLC purchased a new position in Valeant Pharmaceuticals International during the fourth quarter worth about $142,000. Sheaff Brock Investment Advisors LLC purchased a new position in Valeant Pharmaceuticals International during the fourth quarter worth about $200,000. Cetera Investment Advisers purchased a new position in Valeant Pharmaceuticals International during the fourth quarter worth about $208,000. Keybank National Association OH purchased a new position in Valeant Pharmaceuticals International during the fourth quarter worth about $208,000. Finally, Traynor Capital Management Inc. purchased a new position in Valeant Pharmaceuticals International during the fourth quarter worth about $213,000. Hedge funds and other institutional investors own 50.10% of the company’s stock.

A number of research analysts have recently issued reports on the company. Zacks Investment Research upgraded Valeant Pharmaceuticals International from a “sell” rating to a “hold” rating in a research report on Monday, April 2nd. Mizuho upgraded Valeant Pharmaceuticals International from an “underperform” rating to a “neutral” rating and lifted their price target for the stock from $10.00 to $15.00 in a report on Friday. Wells Fargo reiterated a “sell” rating on shares of Valeant Pharmaceuticals International in a report on Tuesday, March 20th. ValuEngine downgraded Valeant Pharmaceuticals International from a “buy” rating to a “hold” rating in a research report on Thursday, March 1st. Finally, Deutsche Bank set a $20.00 target price on Valeant Pharmaceuticals International and gave the company a “buy” rating in a research report on Wednesday, March 21st. Five equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $18.56.

WARNING: This report was first reported by BBNS and is the property of of BBNS. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://baseballnewssource.com/2018/04/07/valeant-pharmaceuticals-intl-inc-vrx-director-buys-153400-00-in-stock/2038381.html.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Receive News & Ratings for Valeant Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.